RZLT
NASDAQ · Biotechnology
Rezolute Inc
$3.79
+0.15 (+4.12%)
Open$3.64
Previous Close$3.64
Day High$3.85
Day Low$3.59
52W High$11.46
52W Low$1.07
Volume—
Avg Volume1.12M
Market Cap375.31M
P/E Ratio—
EPS$-0.75
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+357.8% upside
Current
$3.79
$3.79
Target
$17.35
$17.35
$11.58
$17.35 avg
$20.59
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 45.23M | 44.79M | 46.31M |
| Net Income | 4.09M | 3.84M | 4.53M |
| Profit Margin | 9.0% | 8.6% | 9.8% |
| EBITDA | 6.09M | 5.25M | 5.80M |
| Free Cash Flow | 2.47M | 3.54M | 3.43M |
| Rev Growth | +6.6% | +21.1% | +6.0% |
| Debt/Equity | 0.15 | 0.18 | 0.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |